The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenografts
Jochen Rößler(University Children’s Hospital Bern), Birgit Geoerger(Inserm)
Cited by 61
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors
|Neuro-Oncology|2010|159
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
|PLoS ONE|2015|57
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts
|International Journal of Cancer|2008|56